Neurocrine Biosciences to Participate in Investor Conferences
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is gearing up for a significant presence at a series of prominent investor conferences this coming November. The company has made waves in the biotechnology sector, and these engagements aim to showcase their commitment to advancing neuroscience and improving patient care.
Schedule of Conferences
The exciting events where the Neurocrine team will share their insights include:
2024 UBS Global Healthcare Conference
On November 12, leaders from Neurocrine will present at the highly anticipated 2024 UBS Global Healthcare Conference. CEO Kyle Gano, CFO Matt Abernethy, and Vice-President of Investor Relations Todd Tushla are set to delve into the company’s strategic direction and recent advancements in their treatment offerings. This presentation is scheduled for 1:15 PM Pacific Time, engaging investors with valuable information on Neurocrine's future.
Stifel 2024 Healthcare Conference
Following closely is the Stifel 2024 Healthcare Conference on November 18. Here, also at 10:55 AM Eastern Time, CFO Matt Abernethy, alongside Chief Commercial Officer Eric Benevich, will provide insights into Neurocrine's financial health and commercial strategies. Their discussions will focus on innovative approaches to treatment and business growth.
Jefferies London Healthcare Conference
Concluding this series of presentations, the Jefferies London Healthcare Conference will take place on November 19 at 1:30 PM GMT. This panel will feature CEO Kyle Gano, CFO Matt Abernethy, along with Chief Medical Officer Eiry Roberts. The aim here is to connect with global investors and stakeholders, sharing progress on transformative healthcare initiatives.
Webcast Availability
All presentations will be available via live webcast. Interested investors and stakeholders can access the streams through the Neurocrine Biosciences website. Following the live events, replays will be available approximately one hour after the conclusion and will remain accessible for about a month—a great opportunity for those unable to attend the live sessions.
About Neurocrine Biosciences
Neurocrine Biosciences is at the forefront of neuroscience-focused biopharmaceutical development. The company is dedicated to addressing pressing neurological, neuroendocrine, and neuropsychiatric issues faced by patients today. Neurocrine actively seeks to develop innovative therapeutic solutions, illustrated by its portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia and chorea associated with Huntington's disease.
The company has been diligently working on advancing its pipeline, which showcases several compounds currently in mid- to late-phase clinical development. By leveraging their extensive research in neuroscience, Neurocrine aims to provide significant relief to those suffering from debilitating conditions, underpinned by their mantra, "You Deserve Brave Science." For more details about their mission and developments, visitors can explore their website.
Frequently Asked Questions
1. What is the purpose of Neurocrine’s participation in conferences?
Neurocrine attends these conferences to present their advancements in neurobiopharmaceuticals and to engage with investors on their strategic vision.
2. How can I access the live presentations from these conferences?
The live presentations are accessible via the Neurocrine Biosciences website under the Investors section.
3. Which key executives will represent Neurocrine at the conferences?
CEO Kyle Gano, CFO Matt Abernethy, and CMO Eiry Roberts are among the key executives participating in these events.
4. What does Neurocrine Biosciences focus on?
Neurocrine focuses on developing treatments for neurological disorders and is committed to addressing under-treated conditions in this field.
5. What should potential investors know about Neurocrine?
Investors should recognize Neurocrine as a leader in biopharmaceutical innovation, dedicated to improving patient outcomes through cutting-edge research and development.